Therefore, at this stage, it remains tempting to speculate that in future experiments a combination of Treg-depleting or TGFβ-neutralizing antibody treatments with tumor antigen–targeting antibodies may show synergistic effects in reverting an immunosuppressive TME and, hence, in enhancing the efficacy of treatment. This evidence concerns the gene TGFB1 and neoplasm.